News
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA ... vaccine comprised of an engineered version of RSV F protein antigen. It was first ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results